Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

radioligand therapy

  • You have access
    The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease
    Amar U. Kishan, Shankar Siva, Michael S. Hofman, James Nagarajah, Ana P. Kiess, Phuoc Tran and Jeremie Calais
    Journal of Nuclear Medicine April 1, 2024, 65 (4) 502-509; DOI: https://doi.org/10.2967/jnumed.123.266772
  • First Safety and Efficacy Data with the Radiohybrid <sup>177</sup>Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
    You have access
    First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer
    Alexander Dierks, Alexander Gäble, Andreas Rinscheid, Georgine Wienand, Christian H. Pfob, Malte Kircher, Johanna S. Enke, Tilman Janzen, Marianne Patt, Martin Trepel, Dorothea Weckermann, Ralph A. Bundschuh and Constantin Lapa
    Journal of Nuclear Medicine March 1, 2024, 65 (3) 432-437; DOI: https://doi.org/10.2967/jnumed.123.266741
  • Renal and Multiorgan Safety of <sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
    Open Access
    Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
    Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca, Bernd J. Krause, Michael Lassmann, Walter Jentzen, Jun Tang, Daniela Chicco, Patrick Klein, Lars Blumenstein, Jean-René Basque and Jens Kurth
    Journal of Nuclear Medicine January 1, 2024, 65 (1) 71-78; DOI: https://doi.org/10.2967/jnumed.123.265448
  • Long-Term Nephrotoxicity of <sup>177</sup>Lu-PSMA Radioligand Therapy
    You have access
    Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy
    Lisa Steinhelfer, Lukas Lunger, Lisena Cala, Christian H. Pfob, Constantin Lapa, Philipp E. Hartrampf, Andreas K. Buck, Hannah Schäfer, Christoph Schmaderer, Robert Tauber, Julia Brosch-Lenz, Bernhard Haller, Valentin H. Meissner, Karina Knorr, Wolfgang A. Weber and Matthias Eiber
    Journal of Nuclear Medicine January 1, 2024, 65 (1) 79-84; DOI: https://doi.org/10.2967/jnumed.123.265986
  • An Intrapatient Dosimetry Comparison of <sup>177</sup>Lu-rhPSMA-10.1 and <sup>177</sup>Lu-PSMA-I&amp;T in Patients with Metastatic Castration-Resistant Prostate Cancer
    You have access
    An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
    Andreas Rinscheid, Alexander Gäble, Georgine Wienand, Christian Pfob, Alexander Dierks, Malte Kircher, Martin Trepel, Dorothea Weckermann, Constantin Lapa and Ralph A. Bundschuh
    Journal of Nuclear Medicine December 1, 2023, 64 (12) 1918-1924; DOI: https://doi.org/10.2967/jnumed.123.265970
  • Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
    You have access
    Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
    Vishnu Murthy, Andrei Gafita, Pan Thin, Kathleen Nguyen, Tristan Grogan, John Shen, Alexandra Drakaki, Matthew Rettig, Johannes Czernin and Jeremie Calais
    Journal of Nuclear Medicine November 1, 2023, 64 (11) 1737-1743; DOI: https://doi.org/10.2967/jnumed.122.265155
  • [<sup>177</sup>Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
    You have access
    [177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
    Lorenzo Mercolli, Clemens Mingels, Giulia Manzini, Paul Cumming, Konstantinos Zeimpekis, Song Xue, Ian Alberts, Dominik Uehlinger, Axel Rominger, Kuangyu Shi and Ali Afshar-Oromieh
    Journal of Nuclear Medicine October 1, 2023, 64 (10) 1570-1573; DOI: https://doi.org/10.2967/jnumed.123.265577
  • Albumin-Binding and Conventional PSMA Ligands in Combination with <sup>161</sup>Tb: Biodistribution, Dosimetry, and Preclinical Therapy
    You have access
    Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
    Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli and Cristina Müller
    Journal of Nuclear Medicine October 1, 2023, 64 (10) 1625-1631; DOI: https://doi.org/10.2967/jnumed.123.265524
  • Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
    Open Access
    Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
    Yizhen Pang, Liang Zhao, Jianyang Fang, Jianhao Chen, Lingxin Meng, Long Sun, Hua Wu, Zhide Guo, Qin Lin and Haojun Chen
    Journal of Nuclear Medicine September 1, 2023, 64 (9) 1449-1455; DOI: https://doi.org/10.2967/jnumed.123.265599
  • Safety and Efficacy of [<sup>177</sup>Lu]-PSMA-I&amp;T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
    You have access
    Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
    Robert Tauber, Karina Knorr, Margitta Retz, Isabel Rauscher, Sonia Grigorascu, Kimberley Hansen, Calogero D’Alessandria, Hans-Jürgen Wester, Jürgen Gschwend, Wolfgang Weber, Matthias Eiber and Thomas Langbein
    Journal of Nuclear Medicine August 1, 2023, 64 (8) 1244-1251; DOI: https://doi.org/10.2967/jnumed.122.265259

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
SNMMI

© 2025 SNMMI

Powered by HighWire